Vrabec D P
Department of Otolaryngology, Geisinger Medical Center, Danville, Pennsylvania.
Otolaryngol Clin North Am. 1993 Dec;26(6):1091-114.
Some generalizations regarding fungal infections of the larynx can be made. The reader is cautioned to refer to discussions of the individual infections for exceptions to these generalizations. For the most part, the mycoses are organisms of low pathogenicity emerging as opportunistic organisms thriving in a compromised host. The isolated fungal infections of the larynx reported are exceptions to the rule. Involvement of the larynx and other body sites outside the lung generally indicates a widely disseminated form of the disease. Fungal infections most commonly occur in the immunocompromised patient, including those afflicted with AIDS, cancer, leukemia, and other lymphoreticular neoplasms, patients on long-term corticosteroid therapy, patients with chronic systemic diseases, including diabetes mellitus and severe pulmonary disease, and patients who have undergone successful organ transplantation, which depends on immunologic suppression. Although specific fungi are characteristically found in designated endemic areas, the diseases may surface in remote areas in persons who have recently traveled through the endemic sites. The pathologic picture can be confusing, and pseudoepitheliomatous changes at times resemble malignancy. When atypical features occur in a patient with a suspicious history, special stains and cultures as well as skin tests and serologic studies may be helpful in establishing the diagnosis. For the most part, amphotericin B has been the mainstay of therapy, although the introduction of the newer azole drugs (ketoconazole, itraconazole and fluconazole) may present a breakthrough in the future therapy of these lesions. Ketoconazole has been proven efficacious in certain fungal infections. Itraconazole has recently been released for clinical use. Because of its lower incidence of toxic side effects, it may replace ketoconazole in the therapy of these diseases. Finally, fluconazole, taken orally, effectively crosses the blood-brain barrier; appropriate clinical trials may prove it to be an acceptable agent for those fungi commonly affecting the central nervous system.
关于喉部真菌感染可以得出一些一般性结论。读者需注意,这些一般性结论存在例外情况,具体可参考有关个别感染的讨论。在大多数情况下,真菌病的病原体致病性较低,多为机会性致病菌,在免疫功能受损的宿主中滋生。所报道的孤立性喉部真菌感染是该规律的例外情况。喉部及肺部以外其他身体部位受累通常表明疾病已广泛播散。真菌感染最常发生于免疫功能低下的患者,包括艾滋病患者、癌症患者、白血病患者及其他淋巴网状系统肿瘤患者、长期接受皮质类固醇治疗的患者、患有慢性全身性疾病(包括糖尿病和严重肺部疾病)的患者以及接受成功器官移植(依赖免疫抑制)的患者。虽然特定真菌在指定的流行地区有特征性表现,但疾病也可能在近期去过流行地区的人身上出现在偏远地区。病理表现可能令人困惑,有时假上皮瘤样改变类似恶性肿瘤。当有可疑病史的患者出现非典型特征时,特殊染色、培养以及皮肤试验和血清学研究可能有助于确诊。在很大程度上,两性霉素B一直是主要治疗药物,不过新型唑类药物(酮康唑、伊曲康唑和氟康唑)的引入可能为这些病变的未来治疗带来突破。酮康唑已被证实在某些真菌感染中有效。伊曲康唑最近已获批用于临床。由于其毒副作用发生率较低,可能会在这些疾病的治疗中取代酮康唑。最后,口服氟康唑能有效穿过血脑屏障;适当的临床试验可能证明它是治疗那些常见影响中枢神经系统真菌的可接受药物。